Saphnelo (anifrolumab-fnia) - AstraZeneca
Organ-Specific Treatment Response: Real-World Mucocutaneous and Musculoskeletal Outcomes After 6 and 12 Months of Anifrolumab Treatment (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1277; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Clinical • Real-world • Real-world evidence • Musculoskeletal Diseases
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3568300
 
Amanda Eudy, PhD
 
Sep 8, 2026
 
Prev Next